Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes Haddad, R., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Kasper, S., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Concha-Benavente, F., Monga, M., Lynch, M., Li, L., Shaw, J. W., Gillison, M. L., Harrington, K. J., Ferris, R. L. OXFORD UNIV PRESS. 2017

View details for Web of Science ID 000411324002231